La Jolla Pharmaceutical (LJPC) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
La Jolla Pharma (LJPC) PT Lowered to $45 at SunTrust Robinson Humphrey
August 9, 2018 12:35 PM EDTSunTrust Robinson Humphrey lowered its price target on La Jolla Pharma (NASDAQ: LJPC) to $45.00 (from $57.00) while maintaining a Buy rating following a disappointing quarter on a Giapreza launch.
Analyst Yatin Suneja remains bullish saying they believe patience will eventually be... More
